AEON Biopharma, Inc.(AEON)Earnings, Financials & Key Ratios
AEON•NASDAQ
$0.70
Price updated Jul 7, 2026
AboutAEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.Show more
- Revenue$0
- EBITDA-$13M-117.4%
- Net Income-$39M-193.4%
- EPS (Diluted)-3.95-105.4%
AEON Price & Volume
AEON Biopharma, Inc. (AEON) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- AEON Biopharma faces a precarious outlook as its ABP-450 pipeline development continues to consume capital without generating any commercial revenue, as evidenced by the $2.0 million R&D expenditure in 2026Q1.
- The company's reliance on debt and equity-linked financing to bridge its operational gap has resulted in a deeply negative equity position of -$16.8 million as of 2026Q1.
- Investors should monitor the company's ability to secure non-dilutive funding, as the current cash balance of $6.2 million appears insufficient to sustain long-term clinical operations.
Verdict Logic
the company's liquidity position is severely constrained with only $6.2 million in cash against ongoing quarterly R&D burns of $2.0 million, signaling imminent dilution risk.
AEON Growth Metrics
AEON Biopharma, Inc. (AEON) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-135.54%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-101.69%
Return on Capital
10 Years-1685.32%
5 Years-4971.46%
3 Years-
Last Year-
Peers Comparison
Key metrics vs top competitors for AEON Biopharma, Inc. (AEON)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.70 | $8.28M | -0.18 | — | — | — | — | |
| $0.99 | $3.18M | -0.04 | — | — | -107.66% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — | |
| $1.52 | $36.37M | -1.43 | — | — | -430.93% | — | |
| $254.65 | $449.91B | 107.45 | 8.57% | 5.79% | 67.46% | — | |
| $321.59 | $42.91B | 138.02 | 65.19% | 13.46% | 98.29% | — |
Compare AEON vs Peers
AEON Biopharma, Inc. (AEON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when AEON posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AEON Frequently Asked Questions
AEON Biopharma, Inc. (AEON) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is AEON profitable?
AEON Biopharma, Inc. (AEON) reported a net loss of $60.1M for fiscal year 2025.
Dividend & Returns
What is AEON Biopharma, Inc.'s free cash flow?
AEON Biopharma, Inc. (AEON) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.